

6th International Conference on

Genomics & Pharmacogenomics

September 12-14, 2016 Berlin, Germany

Pharmacogenetics in breast cancer therapy: Patient's genetics profile in Trastuzumab and Tamoxifen prescription

Saeed Tarverdizadeh¹, Ali Hosseini Bereshneh¹, Danesh Soltani¹, Negar Veisi², Mohammad Khademi¹, Reyhane Sadat Saeedi¹ and Mohammad Hossein Modarressi¹

¹Tehran University of Medical Sciences, Iran

²Kermanshah University of Medical Sciences, Iran

Breast cancer that is caused by the accumulation of genetic and epigenetic factors, is one of the main causes of death resulted from cancer. Various therapeutic ways have been introduced for this cancer and the traditional diagnosis and treatment is based on the prognosis estimation using cancer anatomic features (TNM system) and clinical results, but studies show the different responses of these treatments and recurrence after those in some patients. This diversity has resulted by the difference in biological and molecular characteristics. So genomic and molecular studies became more important and the role of targeted treatment based on an individual's genome was highlighted. Today, the progress in personalized medicine using specific individual genome profile has been possible. The ultimate goal of such studies, in the setting of the personalized medicine is providing markers which can be used to risk assessment of progressing disease. This new science cause great development in the treatment of breast cancer by recognition of specific markers and application of targeted treatment like monoclonal antibodies which Trastuzumab and Tamoxifen are the most common examples. The aim of this review is to describe the different aspects of personalized medicine in the breast cancer treatment.

Biography

Saeed Tarverdizadeh is currently a student in Faculty of Medicine, Tehran University of Medical Sciences, Iran. He is also a Member of Students' Scientific Research Center. He has published 3 papers in reputed journals.

Dtarverdi@gmail.com

Notes: